tbuckley/cabot-search huggingface dataset:
Multidimensional model of hope and survival in patients with advanced cancer.
Authors: C. B. Scott, V. T. Chang, M. L. Gonzalez, J. Einhorn, H. Yan, B. Zhou, B. Crump, B. Kasimis
Journal: Journal of Clinical Oncology (2011)

e19575 Background: Understanding the prognosis of advanced cancer patients remains a challenge. Prognostic factors for survival include measures of physical functioning and quality of life, laboratory values, symptoms and comorbidity. Our goal was to develop a multidimensional survival prediction model by combining variables from physiological dimensions, performance status, and patient rated outcomes. Methods: This prospective longitudinal study was approved by the VA New Jersey Health Care System Institutional Review Board. Patients with metastatic cancer whose cancer had already been treated with standard or experimental chemotherapy with KPS < 80%, or who did not wish to receive systemic chemotherapy, were recruited in a specified manner. Measures were taken for each of the dimensions in Wilson and Cleary’s multidimensional model (JAMA 1995;273:59), and the Herth Hope Index. Cox regression and mediation survival analyses were performed. Results: Of 242 patients enrolled, 237 patients were analyzable. The median (M) age was 67 years (range 44-88), with 56% white, 41% black and 3% other; lung (26%) and prostate (18%) were the 2 most common primary sites and M KPS was 60% (range 30-100%). The majority (97%) of patients had died, with M survival of 95 days, range 4-2032 days. In Cox survival analyses of the laboratory values, bilirubin (p<0.001), albumin (p<0.0001), neutrophil count (p<0.0001), and platelet counts (p<0.03) were significantly correlated with survival. In addition to the KPS (p<.0001) and MSAS Physical subscale(p<0.001), Cox analysis identified other patient reported predictors, including patient-rated KPS and the Herth Hope Index (negatively associated p<0.005). Mediation analyses showed that KPS is influenced by platelets, neutropenia, albumin, MSAS SF Physical subscale, MSAS Global Distress Index, and MSAS SF Psychological subscale. KPS directly mediates survival, and affects hope, which also mediates survival. Conclusions: The effect of hope on survival is poorly understood. These findings suggest that physical functioning is related to hope. Patient reported outcomes appear to influence survival.
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs)
Authors: Simona Bernardi, Federica Cattina, Andrea Di Palma, Erika Borlenghi, Francesca Schieppati, Simone Perucca, Valeria Cancelli, Alessandro Turra, Michele Malagola, Crisitina Skert, Carla Filì, Chiara Cattaneo, Angela Passi, Mirko Farina, Giuseppe Rossi, Flavio Mignone, Domenico Russo
Journal: Blood (2015)
Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results.
Authors: A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson, G. R. Blumenschein, H. X. Chen, J. R. Grandis, M. S. Kies
Journal: Journal of Clinical Oncology (2011)

5564 Background: C, an IgG1 monoclonal antibody against EGFR, has established single-agent activity in previously treated SCCHN. VEGF upregulation has been associated with resistance to EGFR inhibitors, thus, combined targeting with C and B, an anti-VEGF humanized monoclonal antibody, may enhance antitumor activity. Methods: Eligible patients had recurrent or metastatic SCCHN, measurable disease and performance status (PS) 0-2. Up to 1 prior regimen (without EGFR inhibitors) for recurrent or metastatic SCCHN and prior chemoradiotherapy with curative intent were allowed. Treatment consisted of C, 250 mg/m2 day 1, 8, 15 given intravenously (IV) (after a loading dose 400 mg/m2 on cycle 1, day 1) and B, 15 mg/kg on day 1 given IV every 21 days, until disease progression or intolerable toxicities. Results: Forty-six eligible patients were enrolled and analyzed (2 patients were ineligible); 44 patients have had prior radiotherapy and 42 prior chemotherapy; 19 patients had received 1 prior palliative chemotherapy regimen; of 44 patients with recurrent disease, 32 recurred within 6 months of prior potentially curative therapy; oropharynx:37%, oral cavity:30%, larynx:15%, others:17%; PS 0:24%, PS 1:67%, PS 2:9%. The median number of cycles was 4 (range, 1-21). Best response in 45 evaluable patients: 8 (18%) partial response, 25 (55%) stable disease, and 12 (27%) progressive disease. The median progression-free survival and overall survival were 2.8 and 7.6 months, respectively. Grade 4 adverse events (AEs): proteinuria, 1; cardiac ischemia, 1; acute renal failure, 1. Grade 3 AEs: hypertension, 3; rash, 4; dysphagia, 6; hemorrhage, 2; infection, 3 and fatigue, 3; esophagitis, 2; pneumonitis, 1; peripheral arterial ischemia, 1. Grade 2 hemorrhage was reported in 4 patients and grade 1 in 6. Two patients died of aspiration pneumonia, one with associated cardiac ischemia and another with acute renal failure; these events were considered unrelated to study drugs. Conclusions: The combination of C with B is well tolerated and active in previously treated patients with SCCHN. Continued study of the regimen is warranted. Supported by U01 CA099168-01.
Removal of an extraluminal gastric gastrointestinal stromal tumor: the role of submucosal tunneling endoscopic resection
Authors: Hejun Zhou, Yuyong Tan, Chunlian Wang, Jingbo Yang, Yuqian Zhou, Deliang Liu
Journal: Endoscopy (2017)

A 47-year-old woman presented with a 10-year history of epigastric discomfort. She had had a thyroid adenoma treated surgically 2 years previously. Esophagogastroduodenoscopy (EGD) revealed a protrusive lesion at the lesser curvature of the gastric corpus ([Fig. 1]). Endoscopic ultrasonography (EUS) revealed that the tumor was originating from the serosal layer and was exhibiting extraluminal growth ([Fig. 2]). Computed tomography (CT) scanning revealed that the lesion was located at the gastric corpus and was protruding into the abdominal cavity ([Fig. 3]; [Video 1]).
Diagnostic work‐up of acute myeloid leukemia
Authors: Olga K. Weinberg, Aliyah R. Sohani, Parul Bhargava, Valentina Nardi
Journal: American Journal of Hematology (2017)

Abstract Acute myeloid leukemia (AML) is characterized by a clonal expansion of undifferentiated myeloid precursors resulting in impaired hematopoiesis and bone marrow failure. In 2016, the World Health Organization (WHO) published revisions to the classification of myeloid neoplasms and acute leukemias. Similar to the 2008 classification, the updated classification incorporates clinical features, morphology, immunophenotyping, and cytogenetics, with greater emphasis on molecular genetics, to define disease entities. This brief review addresses the various components of pathologic assessment to establish a diagnosis of AML and to help risk stratify patients, with an emphasis on newer techniques used in the detection of mutations with prognostic significance, as well as assays employed in the evaluation of minimal residual disease following treatment.
Telomere Elongation In Vivo and Clinical Response Upon Androgen Treatment in a Patient with Aplastic Anemia and a Heterozygous hTERT Gene Mutation,
Authors: Tim H Brümmendorf, Patrick Ziegler, Jamil Akkad, Ute Brassat, Lucia Vankann, Jens Panse, Stefan Wilop, Stefan Balabanov, Klaus Schwarz, Uwe M. Martens, Hubert Schrezenmeier
Journal: Blood (2011)
P1.02-016 HER4 Expression Was Related to the Sensitivity of EGFR-TKI in Non-Small Cell Lung Cancer
Authors: Masaaki Inoue, Junichi Yoshida, Takashi Iwanami, Yusuke Nabe, Masatoshi Kanayama, Daisei Yasuda
Journal: Journal of Thoracic Oncology (2017)
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Authors: Stacy L. Moulder, Virginia F. Borges, Tara Baetz, Tessa Mcspadden, Gina Fernetich, Rashmi K. Murthy, Renae Chavira, Kari Guthrie, Emma Barrett, Stephen K. Chia
Journal: Clinical Cancer Research (2017)

Abstract Purpose: ONT-380 (ARRY-380) is a potent and selective oral HER2 inhibitor. This Phase I study determined the MTD, pharmacokinetics (PK) and antitumor activity of ONT-380 in HER2-positive advanced solid tumors, with an expansion cohort of patients with HER2+ MBC. Experimental Design: ONT-380 was administered twice daily (BID) in continuous 28-day cycles. After a modified 3+3 dose-escalation design determined the MTD, the expansion cohort was enrolled. PK properties of ONT-380 and a metabolite were determined. Response was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST). Results: Fifty patients received ONT-380 (escalation = 33; expansion = 17); 43 patients had HER2+ MBC. Median prior anticancer regimens = 5. Dose-limiting toxicities of increased transaminases occurred at 800 mg BID, thus 600 mg BID was the MTD. Common AEs were usually Grade 1/2 in severity and included nausea (56%), diarrhea (52%), fatigue (50%), vomiting (40%) constipation, pain in extremity and cough (20% each). 5 patients (19%) treated at MTD had grade 3 AEs (increased transaminases, rash, night sweats, anemia, and hypokalemia). The half-life of ONT-380 was 5.38 hours and increases in exposure were approximately dose proportional. In evaluable HER2+ MBC (n = 22) treated at doses ≥ MTD, the response rate was 14% [all partial response (PR)] and the clinical benefit rate (PR + stable disease ≥ 24 weeks) was 27%. Conclusions: ONT-380 had a lower incidence and severity of diarrhea and rash than that typically associated with current dual HER2/EGFR inhibitors and showed notable antitumor activity in heavily pretreated HER2+ MBC patients, supporting its continued development. Clin Cancer Res; 23(14); 3529–36. ©2017 AACR.
P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: Laura Mezquita, Melinda Charrier, Edouard Auclin, Louise Dupraz, Jordi Remon, David Planchard, Maria Gion, Jihene Lahmar, Annas Gazzah, Julien Adam, Nathalie Chaput, Benjamin Besse
Journal: Journal of Thoracic Oncology (2017)
MA09.11 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Authors: Benjamin Besse, Pilar Garrido, Javier Puente, Alexis Cortot, Maria Eugenia Olmedo, Maurice Pérol, Maciej Gil, Grace Chao, Javad Shahidi, Jaafar Bennouna
Journal: Journal of Thoracic Oncology (2017)
Bortezomib Retreatment in Relapsed Multiple Myeloma (MM): Results from a Binational, Multicenter Retrospective Survey
Authors: Irena Hrusovsky, Berthold Emmerich, Albert von Rohr, Monika Engelhardt, Jerome Voegeli, Christian Taverna, Robert Olie, Harold Pliskat, Claas Frohn, Georg Hess
Journal: Blood (2008)
P271 Rates of resectable bronchiectasis and introduction of a referral framework for surgical management of bronchiectasis
Authors: B Barmayehvar, TC Nguyen, A Sullivan, M Kalkat
Journal: Thorax (2016)

<h3>Introduction</h3> Bronchiectasis can cause significant complications and severely impact on patients’ quality of life. The majority of patients can be managed by medical therapy. Although lung resection is a less popular option, it is still reserved for a small number of patients with refractory symptoms, antibiotic-resistant bacteria or complications. The BTS guideline recommends: “Lung resection surgery may be considered in patients with localised disease in whom symptoms are not controlled by medical treatment”. However, the lack of a clear referral framework means respiratory physicians may have missed valuable opportunities to discuss the option of surgery. Thus, we aim to raise awareness about this option among physicians. At a tertiary bronchiectasis clinic, we investigated the proportions of patients with resectable disease and whether appropriate surgical referrals were made. Development of a referral framework was later proposed. <h3>Methods</h3> This is a retrospective study assessing all patients under the care of the bronchiectasis clinic at Queen Elizabeth Hospital Birmingham. The collected data included clinic letters, CT scan and spirometry reports. Based on surgical criteria, we developed a pathway to identify potential candidates for surgery. Their clinic letters were reviewed to determine whether the surgical option had been considered. A literature review was undertaken to identify key factors needed to develop a referral framework. <h3>Results</h3> Among 381 patients identified, 19 patients were excluded having insufficient data and 30 having undergone previous lung resection. In the remaining 322 patients <b>(Figure 1)</b>, 89 patients had localised disease, were fit, with adequate respiratory reserve. In this group, we further identified 8 patients (2% of study population) who were potential candidates for surgery. None of these patients had been considered for surgery. Following a discussion at the Midland Bronchiectasis Network meeting with input from experienced thoracic surgeons, a referral framework was generated to assist physicians in identifying potential candidates. <h3>Conclusions</h3> We identified 8 patients who could benefit from surgery. Although they constitute a small proportion of the study population (2%), the result suggests respiratory physicians may be under-referring patients for surgery. A referral framework is introduced to assist physicians in referring appropriate patients to a surgical team.
A Complement-Dependent Cytotoxicity-Enhancing Anti-CD20 Antibody Mediating Potent Antitumor Activity In the Humanized NOD/Shi-Scid, IL-2Rγnull Mouse Lymphoma Model
Authors: Asahi Ito, Fumihiko Sato, Takashi Ishida, Fumiko Mori, Hisashi Takino, Atsushi Inagaki, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, Ryuzo Ueda
Journal: Blood (2010)
Iron Dextran Versus Iron Sucrose for Non-Hemodialysis Adult Outpatients with Iron Deficiency Anemia: Assessment of Safety and Feasibility for A Randomized Controlled Trial
Authors: Martha L Louzada, Cyrus C. Hsia, Fiona Ralley, Janet Martin, Sarah Connelly, Donna Berta, Valerie Binns, George D Ormond, Ian H. Chin-Yee
Journal: Blood (2011)
ABCG2 Polymorphism Is Associated with Lower Major Molecular Response Rates in CML Patients Treated with 400 Mg Imatinib but Not in Patients Treated with 600 Mg Imatinib.
Authors: Marc Delord, Philippe Rousselot, Jean-Michel Cayuela, Pascale Loiseau, Odile Maarek, Francois Sigaux, Joelle Guilhot, Claude Preudhomme, Francois Guilhot, Fabien Calvo, Heriberto Bruzzoni-Giovanelli
Journal: Blood (2012)
MA10.09 Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response
Authors: Giovanni Rossi, Carlo Genova, Silvia Morbelli, Erka Rijavec, Giulia Barletta, Federica Biello, Claudia Maggioni, Simone Mennella, Maria Giovanna Dal Bello, Roberta Distefano, Matteo Bauckneht, Giuseppe Cittadini, Franco Merlo, Gianmario Sambuceti, Francesco Grossi
Journal: Journal of Thoracic Oncology (2017)
Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.
Authors: Savita Bhalla, Kevin David, Lauren Mauro, Sheila Prachand, Mint Sirisawad, Sriram Balasubramanian, Richard A. Miller, Joseph Buggy, Leo I. Gordon, Andrew M. Evens
Journal: Blood (2007)
MA13.10 Magnetic Resonance Imaging-Guided Delivery of Lung Stereotactic Radiotherapy Using Patient-Controlled Visual Guidance
Authors: Shyama Tetar, Frank Lagerwaard, Miguel Palacios, Niels Haasbeek, Omar Bohoudi, Berend Slotman, Anna Bruynzeel, Suresh Senan
Journal: Journal of Thoracic Oncology (2017)
Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009
Authors: U. Bogdahn, P. Hau, A. Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G. Stauder, K.-H. Schlingensiepen
Journal: Journal of Clinical Oncology (2004)

1514 Background: High-grade gliomas are highly aggressive tumors showing marked transforming growth-factor-beta2 (TGF-β2) overexpression inducing proliferation, metastasis, angiogenesis and in particular immunosuppression. Methods: In 3 phase I/II dose escalation studies adult high-grade glioma patients (WHO III/IV) with recurrent tumor and evidence of tumor progression on MRI were treated with AP 12009, a TGF-β2 specific phosphorothioate antisense oligonucleotide. AP 12009 was administered intratumorally by convection enhanced delivery (CED) in 3 studies in up to 12 cycles. In the 3rd study, an indwelling pump system was used that allowed repeated treatment cycles with a single catheter placement on an out-patient basis. Safety and tolerability were primary endpoints. Secondary endpoint was clinical efficacy. Results: In only 5 of the total 24 patients “possibly” related adverse events were observed, mostly of grade 1 or 2, one was classified as serious. There were no relevant changes in laboratory values, including hematology. Application system and CED were tolerated without problems. Efficacy evaluation resulted in a median overall survival time (mOS) of patients with anaplastic astrocytoma (AA) from start of the first chemotherapy after recurrence of 97.4 weeks, and 44.0 weeks for glioblastoma (GBM) patients as compared to the published data for temozolomide therapy of 42 (AA) and 32 weeks (GBM), respectively. One AA patient had a complete response in all tumor sites after 1 cycle of AP 12009 experiencing an overall survival of 195 weeks after first recurrence. A similar tumor reduction of more than 80% with nearly identical time course was documented for a second AA patient receiving 12 cycles of AP 12009. Additionally, one GBM patient showed a strong reduction in tumor size. Conclusions: These results show AP 12009 mediated TGF-β2 suppression to be a highly promising therapeutic approach for TGF-β overexpressing tumors such as high-grade gliomas. Thus, AP 12009 is now applied in an international phase II/III study in comparison to standard chemotherapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Antisense Pharma Antisense Pharma Antisense Pharma GmbH
Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia
Authors: Sadeer G. Al-Kindi, Anthony DeCicco, Chris T. Longenecker, Jarrod Dalton, Daniel I. Simon, David A. Zidar
Journal: JAMA Cardiology (2017)

Cardiovascular disease affects 1 in 3 patients and remains the leading cause of death in the United States.1 Severe elevation of low-density lipoprotein cholesterol (LDL-C) levels is a modifiable risk factor for developing premature cardiovascular disease, and elevation levels of 190 mg/dL or greater (to convert LDL-C values to millimoles per liter, multiply by 0.0259) may indicate a monogenic etiology such as familial hypercholesterolemia.2 Treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins is recommended (class IA) for all adults 21 years or older with an LDL-C of 190 mg/dL or greater. Statin treatment appears to reduce mortality and result in cost savings for health systems.3,4 Therefore, we sought to examine rates of statin prescription in patients screened for dyslipidemia to identify treatment gaps in a real-world contemporary setting.
Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome.
Authors: Steven Le Gouill, Caroline Bodet-Milin, Françoise Kraeber-Bodere, Anne Moreau, Laurent Campion, Benoit Dupas, Thomas Gastinne, Philippe Moreau, Jean-Luc Harousseau
Journal: Blood (2007)
A Lentiviral Fluorescent Genetic Barcoding System for Flow Cytometry-Based Multiplex Tracking
Authors: Tobias Maetzig, Jens Ruschmann, Courteney K. Lai, Mor Ngom, Suzan Imren, Patricia Rosten, Gudmundur L. Norddahl, Niklas von Krosigk, Lea Sanchez Milde, Christopher May, Anton Selich, Michael Rothe, Ishpreet Dhillon, Axel Schambach, R. Keith Humphries
Journal: Molecular Therapy (2017)

Retroviral integration site analysis and barcoding have been instrumental for multiplex clonal fate mapping, although their use imposes an inherent delay between sample acquisition and data analysis. Monitoring of multiple cell populations in real time would be advantageous, but multiplex assays compatible with flow cytometric tracking of competitive growth behavior are currently limited. We here describe the development and initial validation of three generations of lentiviral fluorescent genetic barcoding (FGB) systems that allow the creation of 26, 14, or 6 unique labels. Color-coded populations could be tracked in multiplex in vitro assays for up to 28 days by flow cytometry using all three vector systems. Those involving lower levels of multiplexing eased color-code generation and the reliability of vector expression and enabled functional in vitro and in vivo studies. In proof-of-principle experiments, FGB vectors facilitated in vitro multiplex screening of microRNA (miRNA)-induced growth advantages, as well as the in vivo recovery of color-coded progeny of murine and human hematopoietic stem cells. This novel series of FGB vectors provides new tools for assessing comparative growth properties in in vitro and in vivo multiplexing experiments, while simultaneously allowing for a reduction in sample numbers by up to 26-fold. Retroviral integration site analysis and barcoding have been instrumental for multiplex clonal fate mapping, although their use imposes an inherent delay between sample acquisition and data analysis. Monitoring of multiple cell populations in real time would be advantageous, but multiplex assays compatible with flow cytometric tracking of competitive growth behavior are currently limited. We here describe the development and initial validation of three generations of lentiviral fluorescent genetic barcoding (FGB) systems that allow the creation of 26, 14, or 6 unique labels. Color-coded populations could be tracked in multiplex in vitro assays for up to 28 days by flow cytometry using all three vector systems. Those involving lower levels of multiplexing eased color-code generation and the reliability of vector expression and enabled functional in vitro and in vivo studies. In proof-of-principle experiments, FGB vectors facilitated in vitro multiplex screening of microRNA (miRNA)-induced growth advantages, as well as the in vivo recovery of color-coded progeny of murine and human hematopoietic stem cells. This novel series of FGB vectors provides new tools for assessing comparative growth properties in in vitro and in vivo multiplexing experiments, while simultaneously allowing for a reduction in sample numbers by up to 26-fold.